LYMEPOLICYWONK: IDSA and Lyme Hearings: TOP 10 Count Down for the Masters of Manipulation?

Byldoadmin

1.       1.     Why did the IDSA rig the voting to preclude guideline change and what are they going to do to comply with the settlement agreement?

2.       2.     Why did they stack the panel in the first place by excluding all treating doctors?

3.       3.     Why did they exclude other doctors who do not treat but were known to have a more open mind?

4.       4.     Why did they make the “open hearing” closed by excluding Lyme patients other than by invitation?

5.5.  5.     Why did they make the “internet” videos all but inaccessible in terms of what people are required to do to watch them? (I’m a technophile and I can’t watch them—that’s ridiculous!)

6.       6.     Why didn’t the IDSA allow Dr. Maloney to testify?

7.       7.     Why didn’t the IDSA conduct its own investigation into the conflicts of interests of the panel members?

8.       8.     Why does the IDSA testify against physicians who don’t follow its guidelines?

9.       9.     Why does the IDSA block legislation that would protect doctors from persecution under their guidelines?

10.   Why does the IDSA pit itself against patients?

Don’t you wish you knew all the “whys and wherefores” for the ins and outs that the IDSA uses to accomplish a goal that puts IDSA reputational and society interests above those of patients?  And, don’t you wish you knew what it would take to change that?  Me too.

You can follow additional comments on Lyme policy at www.lymepolicywonk.org.  You can contact Lorraine Johnson, JD, MBA at lbjohnson@lymedisease.org.

Similar Posts

  • LYMEPOLICYWONK: Spotlight on an IOM Speaker: Does the IOM Know the Difference Between Dogma and Science? Rumor Hassett They Don’t!

    The IOM has slotted Afton Hassett to speak about “Potential Bio-Marker Applications for Lyme Disease: Aligning Multiple Symptoms with Biological Measures”. You might think he was a microbiologist or, or, or ? Well, it turns out that she is a Psy.D. What is a Psy.D.? It is a newish graduate degree in psychology. It does not focus on research or statistics, it focuses on the “soft” side of psychology, generally therapy (which is not a bad thing, but why should it weigh in on biology?) What does a therapist have to say about biomarkers specifically and why was she chosen over say, someone who actually knows about biomarkers, like Dr. Ben Luft? I shudder to think that this is about the psycholigization of an illness—namely turning an illness caused by a bacteria into a psychiatric illness, as in “don’t worry, it’s all in your head”. Afton Hassett, Psy.D., hails from the Chronic Pain & Fatigue Research Center, Department of Anesthesiology at the University of Michigan Medical School. Her view in a nutshell? Is that patients are nuts. How refreshing. She publishes with Dr. Lenny Sigal, a highly vocal anti-chronic Lyme light seeker. How reassuring. Some of her quotes follow after the jump. . .

  • IDSA Virtual Lobby Now Open – VIEW LIVE WEBCAST

    The IDSA Virtual Lobby is now open (see link below). In addition, the IDSA has posted a terms of use on the virtual lobby–these terms are the IDSA's one-sided view of how copyright restrictions etc should play out. You do not need to read the terms before viewing the presentations and you SHOULD NOT. The IDSA is not entitled to post any restrictions on viewing, period, beginning and end of story. I would not want to give them any argument that people read their terms before viewing and the best way to ensure that is to simply not view the terms before viewing.

  • LYMEPOLICYWONK: Lyme disease abandoned by Pharma

    When I first became involved with Lyme disease, I remember wondering where the pharmaceutical interest was in the disease. Most of your double blind controlled trials are funded by the pharmaceutical industry. This means that if your disease is not on their radar, you’re going to have a long hard slog getting funding for studies on the efficacy of different treatments. Diseases that are on the agenda of big Pharma have a distinct advantage in evidence based medicine because studies, typically large scale studies, have been funded by someone with a dog in the hunt. In other diseases, the dog in the hunt may be overzealous, promoting treatments and selling drugs with little proof of effectively. But when a disease is neglected by big Pharma, the opposite occurs. Research simply isn’t done. And, that becomes a social justice issue when insurers and specialty societies deny patients access to care because research studies haven’t been funded and aren’t likely to be funded. Drugs are expensive to develop and research is expensive to conduct. Recently, GlobalDate releases a report that explains why Lyme disease is neglected and is likely to remain neglected by big Pharma.

  • Stimulating distrust?

    On February 17, 2009, President Obama signed into law a stimulus program that includes $1.1 billion for comparative effectiveness research. The Partnership to Improve Patient Care, a coalition of patient groups, physicians and pharmaceuticals, warned that the research might be inappropriately used to “limit treatment options for patients.” A health care e-list that I’m on has become an active war zone on this issue. (Full disclosure—I am a combatant.)

  • LYMEPOLICYWONK: Embers Monkey Trials Part 2: Chronic Lyme Disease Treatment and Persistence

    This is Part 2 of a series on the Embers study of Lyme disease in non-human primates. As described in Part 1 of the series, the Embers monkey research study posed three questions: one regarding treatment of early disseminated Lyme disease, one regarding treatment of late disseminated Lyme disease, and one regarding the ability of the C6 to accurately detect infection. This part of my blog series on the Embers study focuses on the second question–the ability of 90 days of antibiotics to eradicate infection in late disseminated Lyme disease. The researchers defined late disseminated Lyme disease as 27 weeks after inoculation. Rhesus macaques were chosen as the animal model because they experience many of the key signs of human Lyme disease, including neuroborreliosis ( an infection of the brain or nervous system.)